By Christy Santhosh (Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its ...

California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.

A bevy of major corporations and foreign countries have pledged to pour billions into the U.S. since President Donald Trump ...

The stagflation specter is spooking traders today, wiping out the risk-on move that was buoying stocks and weighing on board ...

Aspen Pharmacare posted a 5% rise in half-year earnings on Monday and said it expects double-digit revenue and core profit ...

We recently compiled a list of the Top 10 Stocks to Buy According to Lone Pine Capital. In this article, we are going to take ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Eli Lilly and Company ( NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The ...

Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...